Categories: NewsPharmaceutical

SmartSkin Launches Pharma Seal Assurance Solution to Deliver Real-Time Insights into Container Closure Integrity and Capping Performance

SmartSkin’s ISPE 4.0 debut redefines seal quality in pharma manufacturing.

FREDERICTON, NB, Dec. 1, 2025 /PRNewswire/ – SmartSkin Technologies, a leader in pharmaceutical manufacturing intelligence, today announced the availability of SmartSkin Seal Assurance, a breakthrough solution that gives pharmaceutical manufacturers real-time visibility into seal tightness leading to Container Closure Integrity across vial and cartridge capping. SmartSkin will debut the technology at the upcoming ISPE 4.0 in Barcelona, Spain, highlighting how analytics advance seal quality and reliability in pharmaceutical manufacturing.

SmartSkin Seal Assurance provides per-head, real-time feedback on sealing performance by measuring and visualizing forces during capping. Each event generates a digital signature, creating auditable proof that every capper head is configured and operating within specification. This record helps confirm setup quality and consistency. Compatible with single and multi-head systems, it complements Residual Seal Force (RSF) testing by confirming that sealing conditions measured in RSF are established from the start, closing the loop on Container Closure Integrity assurance.

“Despite the critical importance of seal quality for sterile products, translating the mechanical settings of capping equipment into the physical seal characteristics needed for container-closure performance has not been possible…until now,” said Dr. Mihaela Simianu, Scientific Advisor at SmartSkin Technologies. “SmartSkin’s Seal Assurance opens the possibilities to proactively build container closure integrity assurance into the aseptic process design, creating new possibilities to enhance equipment and process performance in measurable, controllable, and reliable ways

A recent implementation with one of the world’s largest pharma manufacturers demonstrated Seal Assurance’s ability to detect head-specific inconsistencies and identify optimal capping parameters, validating its role as a proactive control solution that enhances both quality and efficiency.

Seal Assurance supports applications from factory acceptance testing (FAT/SAT) and line qualification to routine setup verification and troubleshooting.

About SmartSkin Technologies

SmartSkin Technologies delivers manufacturing intelligence solutions that enable pharmaceutical producers to ensure quality, enhance patient safety, and eliminate costly production issues. By combining advanced Digital Container Twins with real-time analytics, SmartSkin helps manufacturers identify risks, prevent defects, and drive continuous improvement across complex fill-finish and packaging operations. Trusted by global leaders like Schott, Pfizer, and Sanofi, SmartSkin provides the precision and visibility needed to achieve zero-defect production and uphold the highest standards of pharmaceutical manufacturing excellence. Learn more at www.smartskintech.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/smartskin-launches-pharma-seal-assurance-solution-to-deliver-real-time-insights-into-container-closure-integrity-and-capping-performance-302628461.html

SOURCE SmartSkin Technologies

Staff

Recent Posts

More Than a Meal Plan: The Clinical Impact of a Kidney Dietitian

NORTHAMPTON, MA / ACCESS Newswire / December 26, 2025 / Specialized nutrition experts are key…

10 minutes ago

President Trump’s Executive Marijuana Action Exposes the Truth-How the DEA Delayed Medicine While Protecting Everything Else

"Despite clear congressional mandates and FDA authorization, the Drug Enforcement Administration failed to act within…

10 minutes ago

From Follower to Force: China’s Biotech Sector Enters the Global Clinical Mainstream

WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…

3 hours ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…

6 hours ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…

6 hours ago

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…

6 hours ago